Overview
2008Founded1
Compare with Guardant Health, VERACYTE, INC. or CareDx, Inc, or pick any stock.
- TickerCAI on Nasdaq1
- IndustryServices-Medical Laboratories1
- HeadquartersIrving1
- Websitewww.carislifesciences.com
- Incorporated inTX4
- Business address750 W John Carpenter Freeway, Suite 800, Irving, Tx 750394
- Filer category, Emerging growth company4
See how the biggest companies compare on our leaderboards
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
5.6%Operating margin5
-8.4%Net margin5
97.0%Revenue growth, 20255
-11.8%Return on equity5
0.66×Debt to equity5
$66.9MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Molecular Profiling Services brought in 94% of the revenue Caris Life Sciences (United States) broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Molecular Profiling Services | $278.7M | $349.1M | $766.7M |
| Pharma Research And Development Services | $27.4M | $63.1M | $45.3M |
Regions
United States brought in 99% of the revenue Caris Life Sciences (United States) broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $293.4M | $401.8M | $801.4M |
| Outside the United States | $12.7M | $10.4M | $10.6M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development13¢$101.6M
- Other costs87¢$710.4M
Out of $812.0M in revenue.5 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending20¢$16.3M
- Share buybacks0¢$113.0K
- Kept or used elsewhere80¢$66.8M
Out of $83.2M of cash from operations.5
Financial statements
Every line of the income statement in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenue | $812.0M | $412.3M | $306.1M |
| Selling and marketing expense | $167.5M | $152.6M | $142.9M |
| General and administrative expense (see note 11) | $225.0M | $169.4M | $149.1M |
| Research and development expense | $101.6M | $113.9M | $116.9M |
| Total costs and operating expenses | $766.9M | $669.4M | $625.7M |
| Income (Loss) from operations | $45.1M | -$257.1M | -$319.6M |
| Interest income | $16.5M | $7.1M | $11.3M |
| Interest expense | -$56.9M | -$50.0M | -$31.6M |
| Changes in fair value of financial instruments | -$52.3M | $18.5M | $11.1M |
| Other expense, net | -$20.6M | -$349.0K | -$12.6M |
| Total other expense, net | -$113.2M | -$24.8M | -$21.9M |
| Loss before income taxes and provision for income taxes | -$68.1M | -$281.9M | -$341.4M |
| Provision for income taxes | $0 | $0 | $0 |
| Net loss | -$68.1M | -$281.9M | -$341.4M |
| Unrealized gain on available-for-sale securities | $0 | $7.0K | -$1.7M |
| Foreign currency translation adjustments | $726.0K | -$15.0K | $180.0K |
| Comprehensive loss | -$67.4M | -$281.9M | -$342.9M |
| Deemed dividend from Series D redeemable convertible preferred stock (see note 6) | -$384.4M | $0 | $0 |
| Adjustments of redeemable convertible preferred stock to redemption value | -$85.4M | -$96.4M | -$121.1M |
| Net loss attributable to common shareholders basic | -$538.0M | -$378.3M | -$462.5M |
| Net loss attributable to common shareholders diluted | -$538.0M | -$378.3M | -$462.5M |
| Net loss per share attributable to common shareholders, basic (in dollars per share) | -$3.22 | -$10.66 | -$13.24 |
| Net loss per share attributable to common shareholders, diluted (in dollars per share) | -$3.22 | -$10.66 | -$13.24 |
| Weighted-average shares used in computing net loss per share attributable to common shareholders, basic (in shares) | 167.2M shares | 35.5M shares | 34.9M shares |
| Weighted-average shares used in computing net loss per share attributable to common shareholders, diluted (in shares) | 167.2M shares | 35.5M shares | 34.9M shares |
Every line of the balance sheet in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2025-06-30 | 2025-05-31 |
|---|---|---|---|
| Cash, cash equivalents, and restricted cash | $797.8M | ||
| Short-term marketable securities | $2.3M | ||
| Accounts receivable | $112.1M | ||
| Supplies | $63.6M | ||
| Prepaid expenses and other current assets | $21.9M | ||
| Total current assets | $997.8M | ||
| Property and equipment, net | $63.2M | ||
| Goodwill | $19.3M | ||
| Other assets | $45.3M | ||
| Total assets | $1.1B | ||
| Accounts payable | $39.2M | ||
| Accrued expenses and other current liabilities | $87.8M | ||
| Current portion of indebtedness | $169.0K | ||
| Total current liabilities | $127.1M | ||
| Long-term indebtedness, net of debt discounts | $378.8M | ||
| Warrant liabilities | $0 | ||
| Other long-term liabilities | $42.4M | ||
| Total liabilities | $548.4M | ||
| Redeemable convertible preferred stock | $0 | $2.4B | |
| Preferred stock | $0 | ||
| Common stock | $283.0K | ||
| Treasury stock | -$16.9M | ||
| Additional paid-in capital | $3.1B | ||
| Related party promissory note receivable (see note 7) | $0 | ||
| Accumulated deficit | -$2.5B | ||
| Accumulated other comprehensive income | $936.0K | ||
| Total shareholders' equity (deficit) | $577.3M | ||
| Total liabilities, redeemable convertible preferred stock, and shareholders' equity (deficit) | $1.1B | ||
| Temporary equity, authorized (in shares) | 787.4M shares | ||
| Temporary equity, issued (in shares) | 751.1M shares | ||
| Temporary equity outstanding (in shares) | 751.1M shares | ||
| Aggregate Liquidation Preference | $1.9B | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock authorized (in shares) | 100.0M shares | 100.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | ||
| Preferred stock, outstanding (in shares) | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock authorized (in shares) | 2.8B shares | 2.8B shares | |
| Common stock, shares issued (in shares) | 284.1M shares | ||
| Common stock, shares outstanding (in shares) | 282.5M shares | ||
| Common stock, unvested subject to repurchase (in shares) | 23.4K shares | ||
| Treasury stock, shares (in shares) | 1.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$68.1M | -$281.9M | -$341.4M |
| Depreciation and amortization | $22.6M | $48.9M | $49.0M |
| Stock-based compensation expense | $70.0M | $18.6M | $15.2M |
| Non-cash operating lease expense | $5.6M | $5.6M | $4.3M |
| Amortization of debt discounts | $12.8M | $7.1M | $5.4M |
| Changes in fair value of financial instruments | $52.3M | -$18.5M | -$11.1M |
| Loss on debt extinguishment | $19.9M | $0 | $10.9M |
| Other | $1.2M | $4.0M | -$1.3M |
| Accounts receivable | -$29.8M | -$33.8M | -$15.1M |
| Supplies | -$20.8M | $5.5M | -$4.4M |
| Prepaid expenses and other current assets | -$5.2M | -$1.4M | $4.5M |
| Other assets | $48.0K | $121.0K | -$588.0K |
| Accounts payable | $11.0M | -$226.0K | $7.2M |
| Accrued expenses and other liabilities | $11.5M | $803.0K | $1.3M |
| Net cash provided by (used in) operating activities | $83.2M | -$245.2M | -$276.1M |
| Maturities of marketable securities | $0 | $61.4M | $300.5M |
| Purchases of marketable securities | $0 | $0 | -$63.4M |
| Purchases of property and equipment | -$16.3M | -$8.4M | -$22.3M |
| Net cash provided by (used in) investing activities | -$16.3M | $52.9M | $214.8M |
| Proceeds from exercise of stock options | $7.6M | $1.5M | $1.9M |
| Payment of taxes withheld from net settlement of exercised options and vested RSUs | -$18.6M | $0 | $0 |
| Payment of deferred offering costs | -$7.7M | -$1.1M | $0 |
| Payment of third-party debt issuance costs | $0 | $0 | -$2.3M |
| Proceeds from the 2023 term loan, net of issuance costs | $0 | $200.0M | $191.3M |
| Repurchase of common stock | -$113.0K | $0 | $0 |
| Repayment of the Original Term Loans | $0 | $0 | -$180.0M |
| Issuance of the 2025 Convertible Notes, net of issuance costs | $27.9M | $0 | $0 |
| Issuance of the 2025 Warrants | $10.3M | $0 | $0 |
| Payments of 2023 term loan amendment fee | -$4.0M | $0 | $0 |
| Proceeds from initial public offering, net of underwriting discounts and commissions | $528.5M | $0 | $0 |
| Net cash provided by financing activities | $665.0M | $200.3M | $10.1M |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | $130.0K | -$4.0K | $62.0K |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | $732.0M | $8.0M | -$51.1M |
| Interest paid | $43.5M | $49.0M | $15.8M |
| Operating cash flow used for operating leases | $11.6M | $11.3M | $12.1M |
| Operating cash flow used for finance leases | $35.0K | $36.0K | $78.0K |
| Financing cash flow used for finance leases | $106.0K | $157.0K | $743.0K |
| Operating leases | $3.9M | $725.0K | $4.8M |
| Finance leases | $312.0K | $42.0K | $0 |
| Property and equipment included in accounts payable and accrued liabilities | $2.4M | $2.1M | $894.0K |
| Non-cash considerations | $5.9M | $0 | $0 |
| Conversion of redeemable convertible preferred stock to common stock upon initial public offering | $2.4B | $0 | $0 |
| Exercise of warrants upon initial public offering | $147.7M | $0 | $0 |
| Reclassification of deferred offering costs to additional paid-in capital upon initial public offering | $9.0M | $0 | $0 |
Compare Caris Life Sciences (United States) with another company
Timeline
Recent filings
- Sep 23, 20264
- Sep 22, 2026144
- Sep 17, 2026144
- Sep 17, 20264
- Sep 14, 20268-K
- Sep 4, 2026144
- Sep 4, 20264
- Sep 3, 2026144
- Aug 24, 2026144
- Aug 14, 20264
- Aug 14, 20264
- Aug 14, 20264
- Aug 14, 20264
- Aug 14, 20264
- Aug 14, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.carislifesciences.com1
- WikidataQ50039478
- SEC EDGARCIK 2019410
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3Company websiteCaris Life Sciences (United States) logo
- 4
- 5
- 6
- 7